vunakizumab and recaticimab.

Phase 3Monoclonal antibody

XXiangya Hospital of Central South University

vunakizumab and recaticimab. is one of 44 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisNot yet recruiting

PsoriasisPhase 3

Not yet recruiting

Competition

Competitive Landscape

107 competitors in Psoriasis

#DrugCompanyPhaseTrials

Daliresp

AstraZeneca

Phase 3

5 2

Zasocitinib

Takeda

Phase 3

1 3

D-2570

IInventisBio Co., Ltd

Phase 3

4 4

TAK-279

Takeda

Phase 3

3 5

Ponvory

VVanda Pharmaceuticals

Phase 3

1 6

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3

2 7

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 8

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 9

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

3 10

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

Psoriasis

NCT07373847

Clinical

Trials by Indication[1]

Psoriasis1 trial

Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

Not yet recruiting·XXiangya Hospital of Central South University·Phase 4·NCT07373847·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for vunakizumab and recaticimab.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vunakizumab and recaticimab. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vunakizumab and recaticimab.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiangya Hospital of Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: XXiangya Hospital of Central South University

vunakizumab and recaticimab.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News